Background: The 'gold standard' for the diagnosis of melanocytic lesions is dermatopathology. Although most of the diagnostic criteria are clearly defined, the interpretation of histopathology slides may be subject to interobserver variability.
Objectives: The aim of this study was to determine the variability among dermatopathologists in the interpretation of clinically difficult melanocytic lesions.
Methods: This study used the database of MelaFind®, a computer-vision system for the diagnosis of melanoma. All lesions were surgically removed and sent for independent evaluation by four dermatopathologists. Agreement was calculated using kappa statistics.
Results: A total of 1,249 pigmented melanocytic lesions were included. There was a substantial agreement among expert dermatopathologists: two-category kappa was 0.80 (melanoma vs. non-melanoma) and three-category kappa was 0.62 (malignant vs. borderline vs. benign melanocytic lesions). The agreement was significantly greater for patients ≥40 years (three-category kappa = 0.67) than for younger patients (kappa = 0.49). In addition, the agreement was significantly lower for patients with atypical mole syndrome (AMS) (kappa = 0.31) than for patients without AMS (kappa = 0.76).
Limitations: The data were limited by the inclusion/exclusion criteria of the MelaFind® study. This might represent a selection bias. The agreement was evaluated using kappa statistics. This is a standard method for evaluating agreement among pathologists, but might be considered controversial by some statisticians.
Conclusions: Expert dermatopathologists have a high level of agreement when diagnosing clinically difficult melanocytic lesions. However, even among expert dermatopathologists, the current 'gold standard' is not perfect. Our results indicate that lesions from younger patients and patients with AMS may be more problematic for the dermatopathologists, suggesting that improved diagnostic criteria are needed for such patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000336886 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle.
Front Med (Lausanne)
January 2025
Department of Dermatology, Institute of Regenerative Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Vitiligo is an autoimmune disease characterized by the loss of functional melanocytes in the hair follicles and epidermis, leading to white patches on the skin and mucous membranes. Alopecia areata (AA) is a common immune-mediated condition in which autoimmune attack on hair follicles cause non-scarring hair loss. Both diseases significantly impact patients's physical and mental health.
View Article and Find Full Text PDFCollision tumours: our recent experience.
Postepy Dermatol Alergol
December 2024
Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
Introduction: Collision skin lesions (CSL) are rare clinical and pathological entities, posing significant diagnostic and therapeutic challenges. These lesions comprise at least two distinct cell populations - benign and/or malignant neoplasms - that are adjacent yet clearly demarcated. CSL were categorized as collision tumours into three types: two benign lesions, one benign and one malignant lesion, and two malignant lesions, with the most common being basal cell carcinoma (BCC) and melanocytic naevus.
View Article and Find Full Text PDFStudy of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients.
Arch Dermatol Res
January 2025
Dermatology and Venereology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Vitiligo is a pigmentary disorder acquired and caused by the loss or destruction of melanocytes from the epidermis. There is strong proof that vitiligo is mainly an autoimmune disease. Cathelicidin (LL37), an antimicrobial polypeptide, is an important part of the innate immune system and has a role in different skin autoimmune diseases.
View Article and Find Full Text PDF[WHO classification of melanocytic tumours].
Dermatologie (Heidelb)
January 2025
MVZ Dermatohistopathologie Heidelberg, Mönchhofstr. 52, 69120, Heidelberg, Deutschland.
Background: The update of the World Health Organisation (WHO) classification of skin tumours has led to new aspects in the classification of melanocytic tumours.
Objectives: Presentation of the classification of melanocytic tumours in light of current clinical, histological and genetic data.
Materials And Methods: Review of the classification of melanocytic neoplasms in the fifth edition of the WHO classification of skin tumours, taking into account current disease concepts.
The Cell Cycle Regulatory Proteins p16, CDK4, and PTEN Are Unsuitable as Biomarkers in Oral Melanocytic Lesions.
J Oral Pathol Med
January 2025
Division of Oral and Maxillofacial Pathology, School of Dentistry, University of São Paulo, São Paulo, São Paulo, Brazil.
Background: Melanocytic neoplasms are rare in the oral cavity and represent a diagnostic challenge due to the overlap between benign and malignant lesions. However, their pathogenesis is not fully elucidated. The aim of this study was to evaluate the expression of the cell cycle-related proteins p16, CDK4, and PTEN in oral melanocytic nevi and melanomas.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!